Scynexis Inc (SCYX):企業の財務・戦略的SWOT分析

◆英語タイトル:Scynexis Inc (SCYX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH122661FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Scynexis Inc (Scynexis) is a pharmaceutical company that discovers, develops and commercializes novel anti-infective for various therapeutic needs. The company offers pipeline products such as SCY-078, is used for invasive fungal infections; SCY-635, is used for the treatment of Hepatitis C (HCV); SCYX-7158, is used for sleeping sickness; SCY-641, is for human health, among others. Its SCY-078 is a chemical class of glucan synthase inhibitors that blocks target in infectious fungi by interfering with the assembly of the fungal cell wall and prevents the growth of fungal species. Scynexis provides its drug pipeline solutions to pharmaceutical, healthcare and life sciences companies, among others. The company develops products by using technology platforms such as enfumafungin platform, cyclophilin platform and calcineurin platform, among others. Scynexis is headquartered in Jersey City, New Jersey, the US.

Scynexis Inc Key Recent Developments

Mar 29,2021: SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Feb 17,2021: SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China
Feb 17,2021: SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China

This comprehensive SWOT profile of Scynexis Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Scynexis Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Scynexis Inc – Key Information
Scynexis Inc – Overview
Scynexis Inc – Key Employees
Scynexis Inc – Key Employee Biographies
Scynexis Inc – Key Operational Heads
Scynexis Inc – Major Products and Services
Scynexis Inc – History
Scynexis Inc – Company Statement
Scynexis Inc – Locations And Subsidiaries
Scynexis Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Scynexis Inc – Business Description
Scynexis Inc – Corporate Strategy
Scynexis Inc – SWOT Analysis
SWOT Analysis – Overview
Scynexis Inc – Strengths
Scynexis Inc – Weaknesses
Scynexis Inc – Opportunities
Scynexis Inc – Threats
Scynexis Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Scynexis Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Scynexis Inc, Key Information
Scynexis Inc, Key Ratios
Scynexis Inc, Share Data
Scynexis Inc, Major Products and Services
Scynexis Inc, History
Scynexis Inc, Key Employees
Scynexis Inc, Key Employee Biographies
Scynexis Inc, Key Operational Heads
Scynexis Inc, Other Locations
Scynexis Inc, Subsidiaries
Scynexis Inc, Key Competitors
Scynexis Inc, SWOT Analysis
Scynexis Inc, Ratios based on current share price
Scynexis Inc, Annual Ratios
Scynexis Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Scynexis Inc (SCYX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Respira Therapeutics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Respira Therapeutics Inc (Respira) is a pharmaceutical development company that develops dry powder inhaler technologies. The company develops Inhaler technologies to enable targeted lung delivery of drugs to treat pulmonary diseases. It develops products used for the treatment of pulmonary …
  • WESCO International, Inc.:企業の戦略・SWOT・財務情報
    WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report Summary WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • M1 Ltd:企業の戦略的SWOT分析
    M1 Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Blueberry Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Blueberry Therapeutics Ltd (Blueberry Therapeutics) is a provider of nano medicines for the treatment of dermatological disorders. Its pipeline product portfolio includes BB2603-NCE, developed to treat onychomycosis and associated tinea pedis; BB2312 used for the treatment of Acne diseases, …
  • Kasbah Resources Limited:戦略・SWOT・企業財務分析
    Kasbah Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Kasbah Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Suburban Propane Partners, L.P.:企業の戦略・SWOT・財務情報
    Suburban Propane Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Suburban Propane Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Canadian Natural Resources Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Canadian Natural Resources Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Canadian Natural Resources Ltd (Canadian Natural) is an independent upstream oil and gas company. The company carries out acquisition, exploration, development, production, marketing a …
  • Petoro AS:企業の戦略的SWOT分析
    Petoro AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Median Technologies SA (ALMDT):医療機器:M&Aディール及び事業提携情報
    Summary Median Technologies SA (Median) is a medical technology company that develops and markets medical imaging solutions. The company offers clinical trials, imaging services for CT, scientific consulting, image and clinical data management, image data processing and site support, managed service …
  • Tiziana Life Sciences Plc (TILS):企業の財務・戦略的SWOT分析
    Tiziana Life Sciences Plc (TILS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Universal Robina Corp:企業の戦略・SWOT・財務情報
    Universal Robina Corp - Strategy, SWOT and Corporate Finance Report Summary Universal Robina Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Polaris Infrastructure Inc (PIF):企業の財務・戦略的SWOT分析
    Summary Polaris Infrastructure Inc (Polaris Infrastructure), formerly Ram Power Corp is a renewable energy company that explores, acquires, operates and develops geothermal energy projects in Latin America. The company owns and operates San Jacinto Tizate Geothermal project, which is located in nort …
  • Zoologischer Garten Berlin AG:企業の戦略・SWOT・財務情報
    Zoologischer Garten Berlin AG - Strategy, SWOT and Corporate Finance Report Summary Zoologischer Garten Berlin AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Tokyo Electric Power Company Holdings Incorporated (9501):電力:M&Aディール及び事業提携情報
    Summary Tokyo Electric Power Company Holdings Incorporated (TEPCO) is an energy utility. It generates, transmits and distributes electricity; transports fuel; and retails electricity and gas. The company produces power using coal, gas, LNG, solar, wind and hydro sources. TEPCO has presence in the en …
  • Easywell Biomedical Inc (1799)-医療機器分野:企業M&A・提携分析
    Summary Easywell Biomedical Inc (Easywell), formerly Actherm Inc is a health care company that offers medical devices and testing devices. The company offers pharmaceuticals, regenerative medicines and medical devices, among others. Its medical devices comprise pain management systems, non-contact, …
  • Hwange Colliery Co Ltd:企業の戦略・SWOT・財務分析
    Hwange Colliery Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Hwange Colliery Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • RIKEN-製薬・医療分野:企業M&A・提携分析
    Summary RIKEN is a research organization, which carries out research in basic and applied sciences. Its research system consists of strategic research centers, research infrastructure centers, chief scientist system, etc. and a cluster for industry partnerships. Its centers, laboratories and researc …
  • BYD Co Ltd (1211):企業の財務・戦略的SWOT分析
    BYD Co Ltd (1211) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Nuvelution Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Nuvelution Pharma Inc (Nuvelution Pharma) is a developer of late-stage clinical assets. The company offers research and development risk-sharing approach to pharmaceutical and biotechnology companies. It facilitates advancement of late-stage clinical assets where research and development bud …
  • Teekay Offshore Partners L.P.:企業のM&A・事業提携・投資動向
    Teekay Offshore Partners L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Teekay Offshore Partners L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆